B-hPD-L1/hTIGIT Mice

Basic Information

Targeting Strategy

Gene targeting strategy of B-hPD-L1/hTIGIT mice. The exon 3 of mouse Pd-l1 gene that encodes the extracellular domain was replaced by human PD-L1 exon 3 in B-hPD-L1/hTIGIT mice. The exon 2 of mouse Tigit gene that encodes the extracellular domain was replaced by human TIGIT exon 2 in B-hPD-L1/hTIGIT mice.

Details

Phenotype

Protein Expression Analysis

Splenocytes from B-hPD-L1/hTIGIT mice were analyzed by flow cytometry. mTIGIT+ cells were detectable in C57BL/6 mice, while hTIGIT+ cells were detectable in the homozygous B-hPD-L1/hTIGIT mice.

Splenocytes from B-hPD-L1/hTIGIT mice were analyzed by flow cytometry. mPD-L1+ cells were detectable in C57BL/6 mice, while hPD-L1+ cells were detectable in the homozygous B-hPD-L1/hTIGIT mice.

Application

Antibody Efficacy Evaluation

 

Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-L1/hTIGIT mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=7). Combination of hTIGIT Ab and hPD-L1 Ab shows significantly inhibition when compared to single Ab treatment. B-hPD-L1/hTIGIT mouse model is a powerful tool for in vivo evaluation of combination therapy efficacy for hPD-L1 antibodies and hTIGIT antibodies. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

1. J Clin Invest. 2015 May;125(5):2046-58. doi: 10.1172/JCI80445. Epub 2015 Apr 13.
2. Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518.
3. Cancer Cell. 2014 Dec 8;26(6):923-937. doi: 10.1016/j.ccell.2014.10.018. Epub 2014 Nov 26.
4. J Exp Med. 2015 Nov 16;212(12):2165-82. doi: 10.1084/jem.20150792. Epub 2015 Nov 9.